1-8 of 8
Jun Zhou
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P3-11-24: Neoadjuvant Nab-paclitaxel combined with Trastuzumab and Pyrotinib for HER2-enriched subtype of HER2-positive early or locally advanced breast cancer: A multicenter, single-arm, phase 2 trial

Free
Pan Hong, Hui Xie, Yi Ren, Xiaoan Liu, Yi Zhao, Lin Chen, Xiaoming Zha, Tia song Xia, Linlin Zhen, Zhaoji Guo, Jing Lan, Jieqiong Liu, Changchun Li, Jun Zhou, Yanwu Zhang, Zhao Liu, Jing Tao, Shui Wang, Wenbin Zhou
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P3-11-24.
https://doi.org/10.1158/1557-3265.SABCS24-P3-11-24
Published: 13 June 2025
View articletitled, Abstract P3-11-24: Neoadjuvant Nab-paclitaxel combined with Trastuzumab and Pyrotinib for HER2-enriched subtype of HER2-positive early or locally advanced breast cancer: A multicenter, single-arm, phase 2 trial
Journal Articles

CD24hiCD27+ Bregs within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer

Available to Purchase
Huanhuan Huang, Yao Yao, Lesang Shen, Jingxin Jiang, Ting Zhang, Jia Xiong, Jiaxin Li, Shanshan Sun, Siwei Zheng, Fang Jia, Jun Zhou, Xiuyan Yu, Wuzhen Chen, Jun Shen, Wenjie Xia, Xuan Shao, Qingqing Wang, Jian Huang, Chao Ni
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (24): 5227–5243.
https://doi.org/10.1158/1078-0432.CCR-23-1759
Published: 15 December 2023
View articletitled, CD24hiCD27+ Bregs within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer
Open the PDF for CD24hiCD27+ Bregs within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial

Available to Purchase
Ming Lu, Panpan Zhang, Yanqiao Zhang, Zhongwu Li, Jifang Gong, Jie Li, Jian Li, Yan Li, Xiaotian Zhang, Zhihao Lu, Xicheng Wang, Jun Zhou, Zhi Peng, Weifeng Wang, Hui Feng, Hai Wu, Sheng Yao, Lin Shen
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (10): 2337–2345.
https://doi.org/10.1158/1078-0432.CCR-19-4000
Published: 15 May 2020
View articletitled, Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial
Open the PDF for Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial in another window
Journal Articles

The RARS–MAD1L1 Fusion Gene Induces Cancer Stem Cell–like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma

Free
Qian Zhong, Zhi-Hua Liu, Zhi-Rui Lin, Ze-Dong Hu, Li Yuan, Yan-min Liu, Ai-Jun Zhou, Li-Hua Xu, Li-Juan Hu, Zi-Feng Wang, Xin-Yuan Guan, Jia-Jie Hao, Vivian W.Y. Lui, Ling Guo, Hai-Qiang Mai, Ming-Yuan Chen, Fei Han, Yun-Fei Xia, Jennifer R. Grandis, Xing Zhang, Mu-Sheng Zeng
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (3): 659–673.
https://doi.org/10.1158/1078-0432.CCR-17-0352
Published: 31 January 2018
View articletitled, The RARS–MAD1L1 Fusion Gene Induces Cancer Stem Cell–like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma
Open the PDF for The RARS–MAD1L1 Fusion Gene Induces Cancer Stem Cell–like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma in another window
Includes: Supplementary data
Journal Articles

Evaluation of Midkine as a Diagnostic Serum Biomarker in Hepatocellular Carcinoma

Free
Wen-Wei Zhu, Jia-Jian Guo, Lei Guo, Hu-Liang Jia, Ming Zhu, Ju-Bo Zhang, Christopher A. Loffredo, Marshonna Forgues, Hua Huang, Xu-Jian Xing, Ning Ren, Qiong-Zhu Dong, Hai-Jun Zhou, Zheng-Gang Ren, Nai-Qing Zhao, Xin Wei Wang, Zhao-You Tang, Lun-Xiu Qin, Qing-Hai Ye
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (14): 3944–3954.
https://doi.org/10.1158/1078-0432.CCR-12-3363
Published: 15 July 2013
View articletitled, Evaluation of Midkine as a Diagnostic Serum Biomarker in Hepatocellular Carcinoma
Open the PDF for Evaluation of Midkine as a Diagnostic Serum Biomarker in Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition

Free
Xiaofeng Jiang, Jun Zhou, Anita Giobbie-Hurder, Jennifer Wargo, F. Stephen Hodi
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (3): 598–609.
https://doi.org/10.1158/1078-0432.CCR-12-2731
Published: 31 January 2013
View articletitled, The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
Open the PDF for The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition in another window
Includes: Supplementary data
Journal Articles

Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma

Free
Xiaofeng Jiang, Jun Zhou, Noah K. Yuen, Christopher L. Corless, Michael C. Heinrich, Jonathan A. Fletcher, George D. Demetri, Hans R. Widlund, David E. Fisher, F. Stephen Hodi
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (23): 7726–7732.
https://doi.org/10.1158/1078-0432.CCR-08-1144
Published: 01 December 2008
View articletitled, Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma
Open the PDF for Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma in another window
Journal Articles

Concerted Potent Humoral Immune Responses to Autoantigens Are Associated with Tumor Destruction and Favorable Clinical Outcomes without Autoimmunity

Free
Taylor Sittler, Jun Zhou, Joosang Park, Noah K. Yuen, Stefanie Sarantopoulos, Joseph Mollick, Ravi Salgia, Anita Giobbie-Hurder, Glenn Dranoff, F. Stephen Hodi
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (12): 3896–3905.
https://doi.org/10.1158/1078-0432.CCR-07-4782
Published: 16 June 2008
View articletitled, Concerted Potent Humoral Immune Responses to Autoantigens Are Associated with Tumor Destruction and Favorable Clinical Outcomes without Autoimmunity
Open the PDF for Concerted Potent Humoral Immune Responses to Autoantigens Are Associated with Tumor Destruction and Favorable Clinical Outcomes without Autoimmunity in another window